Novel plant-based Antimicrobials against oral pathogens

针对口腔病原体的新型植物抗菌剂

• 批准号: 6833726
• 负责人: Chifu Brad Huang
• 金额: $ 10万
• 依托单位: ORACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-08-01 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6833726
• 关键词: antiinfective agents; beta galactosidase; biotechnology; functional /structural genomics; growth media; high throughput technology; oral bacteria; oral health; plant extracts; plant genetics; recombinant DNA; reporter genes; technology /technique development; tissue /cell culture; antiinfective agents; beta galactosidase; biotechnology; functional /structural genomics; growth media; high throughput technology; oral bacteria; oral health; plant extracts; plant genetics; recombinant DNA; reporter genes; technology /technique development; tissue /cell culture

DESCRIPTION: A novel platform biotechnology, "natural products genomics" for seeking plant-based medicines has been developed which utilizes high throughput screening to identify active compounds in large populations of mutant plant cell cultures. This technology likely accesses the entire range of metabolic products of which the plant is capable. In this regard, plants, particularly their roots, are constantly under attack from bacterial and fungal pathogens that share similarities with those that infect the human oral cavity. The defense mechanisms of plants are therefore a potential source of antimicrobial compounds that may be of value in oral health. This application is to develop methods that will allow the novel platform technology to be applied to the identification and separation of plant compounds that are active against oral pathogens. For this, it is first necessary to develop an ultra high-throughput screen for antimicrobial activity that can be used with very small plant cell cultures. The development of this screen represents the deliverables for Phase I of this STTR. There are two major aspects to this development. First, appropriate pathogen cultures must be developed in which an indicator of cell damage/killing can be used to evaluate efficacy of plant culture secretions. Second, a mechanism for exposing the pathogen cultures to the mutant plant cell cultures must be developed. The application is to explore the possibility that pathogen and plant cultures can be grown on "matching" 96 well plates as co-culture systems, with plant cultures grown in wells with a semi-permeable membrane. The plates can then be placed in contact for 24h, with culture media separated only by the semi-permeable membrane, allowing secreted products from the cultures to diffuse onto the pathogens. If successful, this STTR will represent an extremely valuable transfer of the natural products genomics technology into the field of oral health medications. Compounds discovered by this method should be of considerable economic and medical value as proprietary medicines for the control of oral pathogens.

描述：一种新型的平台生物技术，即用于寻求植物性药物的“天然产品基因组学”，它利用高吞吐量筛选来鉴定大量突变植物细胞培养物中的活性化合物。这项技术可能会访问植物能够的整个代谢产品范围。在这方面，植物，尤其是其根源，一直受到细菌和真菌病原体的攻击，这些病原体与感染人类口腔的病原体相似。因此，植物的防御机制是可能在口腔健康中具有价值的抗菌化合物的潜在来源。该应用程序是开发将允许新型平台技术应用于活跃于口服病原体的植物化合物的识别和分离的方法。为此，首先有必要开发一个超高通量筛选，以进行抗菌活性，该筛选可以与很小的植物细胞培养物一起使用。此屏幕的开发代表了此STTR的I期的可交付成果。这一发展有两个主要方面。首先，必须开发适当的病原体培养物，其中可以使用细胞损伤/杀戮的指标来评估植物培养物的功效。其次，必须开发出一种将病原体培养物暴露于突变植物细胞培养的机制。该应用是为了探索可以在“匹配” 96井板上生长病原体和植物培养物作为共培养系统的可能性，并在具有半渗透膜的井中生长植物培养物。然后可以将板接触24小时，培养基仅由半渗透膜分离，从而使培养基的分泌产物可以扩散到病原体上。如果成功，此STTR将代表将天然产品基因组技术转移到口腔健康药物领域的极其有价值的转移。通过这种方法发现的化合物应具有相当大的经济和医学价值，作为控制口腔病原体的专有药物。